{"id":1623,"date":"2015-01-18T23:04:20","date_gmt":"2015-01-18T23:04:20","guid":{"rendered":"https:\/\/palladiumcapital.com\/?page_id=1623"},"modified":"2022-02-01T13:42:56","modified_gmt":"2022-02-01T13:42:56","slug":"tapimmune-inc-tpiv","status":"publish","type":"page","link":"https:\/\/www.palladiumcapital.com\/client-profiles\/tapimmune-inc-tpiv\/","title":{"rendered":"TapImmune, Inc."},"content":{"rendered":"<table>\n<tbody>\n<tr>\n<td colspan=\"4\">\n<table class=\"client-links aligncenter\" align=\"center\">\n<tbody>\n<tr>\n<td><a href=\"http:\/\/www.tapimmune.com\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-full wp-image-1577\" src=\"https:\/\/palladiumcapital.com\/wp-content\/uploads\/2015\/01\/icon-home.gif\" alt=\"icon-home\" width=\"35\" height=\"34\" \/><\/a><\/td>\n<td><a href=\"http:\/\/finance.yahoo.com\/echarts?s=TPIV+Interactive#\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-full wp-image-1576\" src=\"https:\/\/palladiumcapital.com\/wp-content\/uploads\/2015\/01\/icon-chart.gif\" alt=\"icon-chart\" width=\"30\" height=\"34\" \/><\/a><\/td>\n<td><a href=\"http:\/\/finance.yahoo.com\/q?s=TPIV&amp;ql=1\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-full wp-image-1578\" src=\"https:\/\/palladiumcapital.com\/wp-content\/uploads\/2015\/01\/icon-info.gif\" alt=\"icon-info\" width=\"30\" height=\"34\" \/><\/a><\/td>\n<td><a href=\"http:\/\/www.google.com\/search?hl=en&amp;gl=us&amp;tbm=nws&amp;authuser=0&amp;q=%22ChromaDex+Corporation%22&amp;oq=%22ChromaDex+Corporation%22&amp;gs_l=news-cc.3..43j43i53.620838.622472.0.623915.3.2.0.1.0.0.95.179.2.2.0...0.0...1ac.1.I9UJ4M-YIx4&amp;gws_rd=ssl#safe=active&amp;hl=en&amp;gl=us&amp;authuser=0&amp;as_qdr=all&amp;tbm=nws&amp;q=%22TapImmune%2C+Inc.+Corporation%22\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-full wp-image-1579\" src=\"https:\/\/palladiumcapital.com\/wp-content\/uploads\/2015\/01\/icon-news.gif\" alt=\"icon-news\" width=\"39\" height=\"33\" \/><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\">\n<table class=\"tombstones aligncenter\">\n<tbody>\n<tr>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease.<\/p>\n<p>The Company\u2019s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients\u2019 killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing).<\/p>\n<p>The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities.<\/p>\n<p>TapImmune is conducting clinical trials and R&amp;D programs, to explore the promising\u00a0commercial potential of our comprehensive approach to immunotherapy that stimulates Helper T-cells; Killer T-cells and enhances antigen presentation.<\/p>\n<p>This all-encompassing approach makes TapImmune a leading innovator and world class immunotherapy company.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company\u2019s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients\u2019 killer T-cells, helper T-cells and to restore or further augment antigen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2650,"parent":22,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/client-profile.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/pages\/1623"}],"collection":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/comments?post=1623"}],"version-history":[{"count":1,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/pages\/1623\/revisions"}],"predecessor-version":[{"id":2651,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/pages\/1623\/revisions\/2651"}],"up":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/pages\/22"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/media\/2650"}],"wp:attachment":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/media?parent=1623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}